70476-82-3 Usage
Description
Different sources of media describe the Description of 70476-82-3 differently. You can refer to the following data:
1. Mitoxantrone hydrochloride is the first of the synthetic anthracenediones related
to doxorubicin to reach the marketplace. Mitoxantrone is useful in the treatment
of advanced localized and metastatic mammary carcinomas. It is reported to be
less cardiotoxic than doxorubicin.
2. Mitoxantrone is an anthraquinone that intercalates in DNA and inhibits topoisomerase II (IC50 = 5.3 μM), thus inhibiting cell proliferation. It also inhibits HIV-1 integrase (IC50 = 3.8 μM). Mitoxantrone is exported from cells in an ATP- and glutathione-dependent manner by multidrug resistance protein-1. Formulations containing mitoxantrone have been used in the treatment of cancer and multiple sclerosis.
Chemical Properties
Dark blue, electrostatic, hygroscopic powder.
Originator
Lederle (USA)
Uses
Different sources of media describe the Uses of 70476-82-3 differently. You can refer to the following data:
1. Mitoxanthrone hydrochloride USP (Novantrone) is used to traet acute nonlymphocytic leukemia, including myelogenous promyelocytic, monocytic, and erythroid acute leukemias.
2. Mitoxantrone dihydrochloride is an antiviral, antibacterial, antiprotozoal, immunomodulating, and antineoplastic cytostatic anthraquinone derivative. Induces DNA damage by intercalating into DNA and inhibiting Topo II (topoisomerase II). Mitoxantrone dihydrochloride induces interstrand DNA cross-links and DNA-protein cross-links in cellular systems. Mitoxantrone dihydrochloride has recently been shown to be an inhibitor of DNA methylation.
Therapeutic Function
Antineoplastic
General Description
Mitoxantrone is supplied as a blue aqueous solution in 10-and 20-mg vials for IV administration in the treatment of acute lymphoid leukemia, acute myeloid leukemia, breastcancer, prostate cancer, non-Hodgkin’s lymphoma, andmultiple sclerosis. The mechanisms of resistance are thesame as those seen for the anthracyclines. The distributionhalf-life is 1.1 to 3.1 hours, and the drug has a large volumeof distribution (11 L/kg). The elimination half-life rangedfrom 23 to 215 hours, and elimination was primarily via thebile. Metabolism of the agent involves oxidation of the sidechainalcohols to give the monocarboxylic and dicarboxylicacids.Other toxicities are those seen for the anthracyclinesand include myelosuppression, nausea, vomiting, mucositis,diarrhea, and alopecia. The intense color of the parent drugand metabolites may turn the urine blue.
Biochem/physiol Actions
Mitoxantrone is a cytostatic anthracenedione that intercalates in DNA and increases the incidence of double-strand breaks by stabilizing the cleavable complex of topoisomerase II and DNA. Mitoxantrone also displays broad immunosuppressive activity inhibiting proliferation of all classes of lymphocytes and inducing apoptosis of antigen-presenting T cells. It used clinically as a chemotherapeutic agent against leukemias and solid tumors and as an immune system modulator in multiple sclerosis.
Clinical Use
Mitoxantrone is used in combination with other agents during the initial treatment of acute nonlymphocytic leukemia and hormone-refractory prostate cancer. Recent studies have shown that mitoxantrone also decreases the rate of relapse and disease progression in patients with multiple sclerosis. Although too toxic for use in patients with primary progressive disease, it is available for the treatment of chronic progressive, progressive relapsing, or deteriorating relapsing-remitting multiple sclerosis.
Metabolism
Mitoxantrone excretion primarily is biliary. Both the unchanged drug and inactive metabolites resulting from N-dealkylation, deamination, and oxidation of the resultant aldehyde to the carboxylic acid are observed. Both arms of the structure can be metabolized, leading to mono- or dicarboxylic acid metabolites, which are excreted as the glucuronide conjugate. The conjugated metabolites are an intense, dark blue in color and will result in blue-green urine.
Check Digit Verification of cas no
The CAS Registry Mumber 70476-82-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,0,4,7 and 6 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 70476-82:
(7*7)+(6*0)+(5*4)+(4*7)+(3*6)+(2*8)+(1*2)=133
133 % 10 = 3
So 70476-82-3 is a valid CAS Registry Number.
InChI:InChI=1/C22H28N4O6.3ClH/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32;;;/h1-4,23-30H,5-12H2;3*1H
70476-82-3Relevant articles and documents
Novel anti-tumor compounds and application thereof
-
Paragraph 0085-0090, (2019/12/25)
Mitoxantrone hydrochloride type [nu] and [omega] compounds are easier to prepare and more conducive to reducing energy consumption, have less hygroscopicity, better storage stability and the like, andare suitable for application in preparation of drugs for treatment or prevention of malignant lymphoma, breast cancer, acute leukemia, lung cancer, melanoma, soft tissue sarcoma, multiple myeloma, recurrent optic neuritis, multiple sclerosis and the like.
A new way of synthesizing 1,4-bis-substituted aminoalkylamino-anthraquinones
Dzieduszycka,Stefanska,Kolodziejczyk,Borowski,Martelli
, p. 219 - 226 (2007/10/02)
-
1,4-Bis(substituted-amino)-5,8-dihydroxyanthraquinones and leuco bases thereof
-
, (2008/06/13)
This disclosure describes symmetrical 1,4-bis(substituted-amino)-5,8-dihydroxyanthraquinones useful as chelating agents and for inhibiting the growth of transplanted mouse tumors.
